Nursing News

Drug doesn't significantly lower risk of major heart problems in dialysis patients

 

Stanford, CA, USA (November 5, 2012) - In one of the largest and longest trials involving patients with kidney failure, a study led by an international team of researchers found that cinacalcet — a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism — does not significantly reduce the risk of death or major cardiovascular events.

 

FDA expands use of Xarelto to treat, reduce recurrence of blood clots

 

Silver Spring, MD, USA (November 2, 2012) - The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

 

Study suggests too much risk associated with SSRI usage and pregnancy

 

Antidepressants should only be prescribed with great caution

 

Boston, MA, USA (October 31, 2012) – Elevated risk of miscarriage, preterm birth, neonatal health complications and possible longer term neurobehavioral abnormalities, including autism, suggest that a class of antidepressants known as selective serotonin reuptake inhibitors (SSRI) should only be prescribed with great caution and with full counseling for women experiencing depression and attempting to get pregnant, say researchers at Beth Israel Deaconess Medical Center, Tufts Medical Center and MetroWest Medical Center.

 

Researchers invent a quick-release medical tape that minimizes neonatal skin injury

No more tears from tears

 

Boston, MA, USA (October 29, 2012) Commercial medical tapes on the market today are great at keeping medical devices attached to the skin, but often can do damage—such as skin tissue tearing—once it's time to remove them. A research team from Brigham and Women's Hospital (BWH) has invented a quick-release tape that has the strong adhesion properties of commercial medical tape, but without the ouch factor upon removal.

The team was led by Jeffrey Karp, PhD, BWH Division of Biomedical Engineering, Department of Medicine, senior study author in collaboration with The Institute for Pediatric Innovation which defined the need and requirements for a new neonatal adhesive based on national surveys of neonatal clinicians.

 

Hot flashes can come back after SSRI

 

Cleveland, Ohio, USA (October 24, 2012) - Hot flashes and night sweats can return after women stop using escitalopram—an antidepressant—to treat these menopause symptoms, according to a study published online this month in Menopause, the journal of the North American Menopause Society. This is typical of stopping hormone therapy as well.

 

Can Diabetes Devices be Damaged by Airport Security Scanners?

 

New Rochelle, NY(October 24, 2012) — Full-body or X-ray scanners used for airport security screening may affect the function of insulin pump or continuous glucose monitoring (CGM) devices. People with diabetes can present a travel letter obtained from their physicians to avoid possible damage caused by exposure to imaging equipment in airports. The risk to these sensitive devices posed by scanners and the low-pressure conditions on airplanes are the focus of the Editorial “Navigating Airport Security with an Insulin Pump and/or Sensor,” published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The Editorial is available free on the Diabetes Technology & Therapeutics website.

 

Results of the TRILOGY ACS Angiographic Cohort presented at TCT 2012

Study finds that prasugrel may reduce cardiovascular events among patients managed medically after an angiogram for acute coronary syndrome

 

Miami, FL, USA (October 24, 2012) – A study has found that the anti-clotting medication prasugrel reduced cardiovascular events among patients who present with an acute coronary syndrome and are managed medically after an angiogram is performed to determine coronary anatomy. Results of the TRILOGY ACS trial, Angiographic Cohort were presented today at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

 

Challenging Parkinson's dogma

 

Boston, MA, USA (October 24, 2012) - Scientists may have discovered why the standard treatment for Parkinson's disease is often effective for only a limited period of time. Their research could lead to a better understanding of many brain disorders, from drug addiction to depression, that share certain signaling molecules involved in modulating brain activity.

 

Study of Heavily Pre-Treated Myeloma Patients

Pomalidomide Demonstrated Significant Progression-Free Survival and Overall Survival Advantages in Phase III

 

Boudry, Switzerland (October 23, 2012) - Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) today announced that its phase III, multi-center, randomized, open-label study (MM-003) of pomalidomide plus low-dose dexamethasone compared to high-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma was reviewed by a data safety monitoring board (DSMB). The DSMB determined MM-003 met the primary endpoint of improvement in progression-free survival (PFS) at the PFS final analysis. Additionally, at the OS interim analysis, the study crossed the superiority boundary for overall survival (OS), a key secondary endpoint that the study was also powered to evaluate. Improvements in PFS and OS were both highly statistically significant and clinically meaningful. As a result, the DSMB recommended that patients who had not yet progressed in the high-dose dexamethasone arm should be crossed-over to the pomalidomide plus low-dose dexamethasone arm.

 

Excessive ICU noise may harm patients

 

Atlanta, Georgia, USA (October 22, 2012) - New research shows that overnight noise levels in the medical ICU (MICU) often exceed recommended levels, which could potentially lead to worse outcomes. Researchers from Yale University School of Medicine reviewed 70 MICU patient charts and recorded in-room activities between midnight and 4:00 AM. Based on this chart review and via direct observation, they also identified the key elements of nocturnal patient disruption.

 

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 15-18 October 2012

London (October 19, 2012) - At the start of its October 2012 meeting, the Committee for Medicinal Products for Human Use (CHMP) elected Dr Ian Hudson as its new vice-chair for a three-year mandate.
Dr Hudson brings outstanding experience and expertise from a long career in regulatory medicine and drug development, particularly in the areas of anti-infectives and oncology. He currently holds the position of Director of the Licensing Division at the Medicines & Healthcare Products Regulatory Agency in London. Dr Hudson has been a member of CHMP since 2004.
The opinions adopted by the CHMP at the October 2012 meeting and other important outcomes are listed in the table below.

European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs

 

Pharmacovigilance Risk Assessment Committee (PRAC) to consider need for updated treatment advice for diclofenac in follow-on review

 

London, UK (October 19, 2012) - The European Medicines Agency has finalised a review of recently published information on the cardiovascular safety of non-steroidal anti-inflammatory drugs (NSAIDs).

The Agency’s Committee for Medicinal Products for Human Use (CHMP) concluded that evidence from newly available published data sources, including meta-analysis of clinical trials and observational studies, and the results of a European Union-funded independent research project, the ‘safety of non-steroidal anti-inflammatory drugs' (SOS) project, on the cardiovascular safety of this class of medicines confirm findings from previous reviews, conducted in 2005 and 2006.

 

European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy

 

No new concerns for Pandemrix or other vaccines on the basis of available evidence

 

London (October 19, 2012) - The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), at the request of the Agency’s Executive Director Guido Rasi, has reviewed preliminary research results by the Finnish National Institute of Health and Welfare (THL) investigating differences in the immunological response triggered by different pandemic influenza vaccines as a potential root cause for the development of narcolepsy in persons vaccinated with Pandemrix.

 

European Medicines Agency recommends approval of first higher-strength insulin for treatment of patients with diabetes mellitus in the EU

 

London, UK (October 19, 2012) - The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has made a recommendation to give marketing authorisation to insulin degludec, a new basal analogue insulin for the treatment of diabetes mellitus in adults. It is introduced in a pre-filled pen in two formulations – 100 units/ml and 200 units/ml.

 

Commonsense medical precautions ignored

Wide discrepancy in surveillance and control of infections in ICUs

 

New York, NY, USA (October 15, 2012) - Screening practices for multidrug-resistant organisms (MDROs) in intensive care units (ICUs) vary widely from hospital to hospital, according to a new study by researchers at Columbia University School of Nursing and published in the October 2012 issue of the American Journal of Infection Control.

Researchers found that of the hospitals surveyed, a little more than half (59 percent) routinely screened for methicillin-resistant Staphylococcus aurea, or MRSA. Other potentially deadly MDROs were screened for far less frequently: vancomycin-resistant Enterococcus (22 percent), gram-negative rods (12 percent), and C. difficile (11 percent).

 

Kidney failure patients may be facing accelerated aging process

Quiz could determine death risk for kidney dialysis patients of all ages

 

Baltimore, Maryland, USA (October 12, 2012) - A simple six-question quiz, typically used to assess disabilities in the elderly, could help doctors determine which kidney dialysis patients of any age are at the greatest risk of death, new Johns Hopkins research suggests.

 

Hospitals that cooperate on infection control fare better than hospitals acting alone

 

PITTSBURGH, PA, USA (October 9, 2012) – An individual hospital's infection control efforts have a ripple effect on the prevalence of a deadly and highly infectious bacterium in hospitals throughout its surrounding region, a multi-center research group led by the University of Pittsburgh demonstrated in a computer simulation-based study.

 

NICE consults on new hypertension draft quality standard

 

London, UK (October 5, 2012) - NICE has today (5 October) launched a consultation on its draft quality standard for the management of patients with hypertension. NICE quality standards aim to help commissioners, healthcare and service providers deliver the best levels of quality, evidence-based patient care. They are derived from the best available evidence (usually NICE guidance or NICE accredited sources), and apply right across the NHS in England. The draft quality standard on hypertension describes measurable markers of high-quality, cost-effective care to drive improvements in the effectiveness, safety and experience of care for people with hypertension.

 

Focus Diabetes

Process & technology innovation need to be employed in structured care

 

  • Personalized Diabetes Management supports improved diabetes therapy outcomes

 

Berlin, Germany (October 1, 2012) - Diabetes is a silent chronic disease in the beginning, but if not treated appropriately it deteriorates over time. Due to its secondary complications diabetes can be reckoned as dangerous. It requires healthcare professionals’ and patients’ continuous attention and therapy adaptation to optimally manage the condition to delay or even prevent the sequelae to arise. At the 2nd international scientific media symposium Focus Diabetes: Patients. Perspectives. Progress., facilitated by Roche Diabetes Care on the occasion of the 48th annual meeting of the European Association for the Study of Diabetes (EASD) in Berlin, renowned key opinion leaders discussed most recent approaches to personalize diabetes management and optimally manage glycemic control with the support of latest technological innovations. There was consensus amongst the experts about the fact that the presented concepts are able to substantially facilitate therapy decisions and are easy to implement into daily routines. This is in addition emphasized by current study results which demonstrate that the structured management of glycemic patterns in combination with data visualization can support enhanced doctor-patient collaboration, and can lead to patient motivation to better adherence and improved therapy outcomes1.

 

Bayer HealthCare supports individualized diabetes treatment

What people with diabetes do really need

 

  • A patient-oriented approach is pivotal of successful blood glucose therapy

 

Berlin, Germany (October 1, 2012) – Bayer HealthCare is stressing the need to help health care professionals and people with diabetes to make better decisions for effective diabetes management. At a media round table organized on the occasion of the 48th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany, a group of international experts came to the conclusion that a patient-focused approach combined with modern blood glucose monitoring systems of the next generation is pivotal of a successful future diabetes therapy. They agreed that standardized guidelines and accuracy norms for blood glucose monitoring systems are essential, however, each therapy might be individual to human behavior and constituency as many patients are still failing, for example, to reach HbA1c goals.

 

Rutgers College of Nursing professor's research links increased hospital infections to nurse burnout

 

Newark, New Jersey, USA (September 28, 2012) - According to the Centers for Disease Control and Prevention, each year nearly 100,000 hospitalized patients die from infections acquired while undergoing treatment for other conditions. While many factors may contribute to the phenomenon, nurse staffing (i.e., the number of patients assigned to a nurse) has been implicated as a major cause.

 

NICE issues final guidance on the use of drug to reduce the long term impact of strokes

 

London, UK (September 26, 2012) - NICE, the healthcare guidance body, has today (26 September) issued final guidance on the use of alteplase (Actilyse, Boehringer Ingelheim) for the treatment of acute ischaemic stroke. NICE has recommended alteplase within the NHS as long as treatment is started as early as possible within 4.5 hours after onset of stroke symptoms, and after intracranial haemorrhage has been excluded by appropriate imaging techniques.

 

New FDA task force will support innovation in antibacterial drug development

 

Silver Spring, MD, USA (September 24, 2012) - The U.S. Food and Drug Administration today announced the formation of an internal task force that will support the development of new antibacterial drugs, a critical public health care goal and a priority for the agency.

 

EMA: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2012

 

London, UK (September 21, 2012) - At the start of its September 2012 meeting, the Committee for Medicinal Products for Human Use (CHMP) elected Tomas Salmonson as its new chair for a three-year mandate.

Dr Salmonson brings outstanding experience and expertise from a long career in the regulation of medicines both on a national and European level to his new role. A pharmacist by training, he is currently senior scientific advisor at the Swedish Medical Products Agency (MPA). He has been a member of the CHMP for more than 12 years.

European Medicines Agency recommends first medical treatment for removal of eschar from severe burn wounds

 

Pineapple enzyme-based debriding agent adds new treatment option for burn wounds care management

 

London, UK (September 21, 2012) - The European Medicines Agency has recommended approval of NexoBrid (concentrate of proteolytic enzymes enriched in bromelain), an orphan-designated medicine, for removal of eschar in adult patients with deep partial- and/or full-thickness thermal burn. Eschar is the dried-out, thick, leathery, black necrotic tissue that covers severe burn wounds. Its removal is essential to initiate the wound healing process and prevent further complications such as infections in burn victims.

 

Preemies' brains reap long-term benefits from Kangaroo Mother Care

 

Quebec City, Canada (September 19, 2012) Kangaroo Mother Care -- a technique in which a breastfed premature infant remains in skin-to-skin contact with the parent's chest rather than being placed in an incubator -- has lasting positive impact on brain development, revealed Université Laval researchers in the October issue of Acta Paediatrica. Very premature infants who benefited from this technique had better brain functioning in adolescence -- comparable to that of adolescents born at term -- than did premature infants placed in incubators.

 

Home birth

Birth is no reason to go to hospital

 

Copenhagen, Denmark (September 19, 2012) - A new Cochrane Review concludes that all countries should consider establishing proper home birth services. They should also provide low-risk pregnant women with information enabling them to make an informed choice. The review has been prepared by senior researcher, statistician Ole Olsen, the Research Unit for General Practice, University of Copenhagen, and midwifery lecturer PhD Jette Aaroe Clausen.

 

New NICE quality standard for antenatal care

 

London, UK (September 17, 2012) - NICE has today (17 September) launched a new quality standard on the care that should be offered to women during their pregnancy. This new quality standard on antenatal care represents the first component of a suite of maternity quality standards which, along with intrapartum care and postnatal care, will form the core pathway. Other quality standards in development include hypertension in pregnancy, caesarean section and multiple pregnancy.

 

Study finds Gingko Biloba does not improve cognition in MS patients

 

Results come after 2005 pilot study offered hope that supplement may have offered benefits

 

Portland, Oregon, USA (September 13, 2012) - Many people with multiple sclerosis for years have taken the natural supplement Gingko biloba, believing it helps them with cognitive problems associated with the disease.

 

FDA approves new multiple sclerosis treatment Aubagio

 

Silver Spring, MD, USA (September 12, 2012) - The U.S. Food and Drug Administration today approved Aubagio (teriflunomide), a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).

 

Simple tool may help inexperienced psychiatrists better predict violence risk in patients, U-M study finds

 

Without assessment tool, inexperienced psychiatrists less likely to accurately predict violence

 

Ann Arbor, Mich., USA (September 4, 2012) - Inexperienced psychiatrists are less likely than their veteran peers to accurately predict violence by their patients, but a simple assessment checklist might help bridge that accuracy gap, according to new research from the University of Michigan.

Led by psychiatrist Alan Teo, M.D., a Robert Wood Johnson Foundation Clinical Scholar of the University of Michigan, researchers examined how accurate psychiatrists were at predicting assaults by acutely ill patients admitted to psychiatric units.

 

New long-term antimicrobial catheter developed

 

Spencers Wood, UK (September 4, 2012) - A novel antimicrobial catheter that remains infection-free for up to twelve weeks could dramatically improve the lives of long-term catheter users. The scientists who have developed the new technology are presenting their work at the Society for General Microbiology's Autumn Conference at the University of Warwick.

 

Revatio (sildenafil)

Drug Safety Communication - Recommendation Against Use in Children

 

Silver Spring, MD, USA (August 30, 2012) - FDA notified healthcare professionals and their medical care organizations that Revatio (sildenafil) should not be prescribed to children (ages 1 through 17) for pulmonary arterial hypertension (PAH).This recommendation against use is based on a recent long-term clinical pediatric trial showing that: (1) children taking a high dose of Revatio had a higher risk of death than children taking a low dose and (2) the low doses of Revatio are not effective in improving exercise ability. Treatment of PAH in children with this drug is an off-label use (not approved by FDA) and a new warning, stating the use of Revatio is not recommended in pediatric patients has been added to the Revatio labeling.

 

FDA approves Linzess to treat certain cases of irritable bowel syndrome and constipation

 

Silver Spring, MD, USA (August 30, 2012) - The U.S. Food and Drug Administration today approved Linzess (linaclotide) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation (IBS-C) in adults. According to the National Institutes of Health, an estimated 63 million people are affected by chronic constipation. Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and do not respond to standard treatment. Additionally, an estimated 15.3 million people are affected by IBS. IBS-C is a subtype characterized mainly by abdominal pain and by hard or lumpy stools at least 25 percent of the time and loose or watery stools less than 25 percent of the time.

 

Nurse Leader Resistance Perceived as a Barrier to High-Quality, Evidence-Based Patient Care

 

COLUMBUS, Ohio (August 28, 2012) - A new national survey of more than 1,000 registered nurses suggests that serious barriers - including resistance from nursing leaders - prevent nurses from implementing evidence-based practices that improve patient outcomes. When survey respondents ranked these barriers, the top five included resistance from nursing leaders and nurse managers - a finding that hasn’t been reported in previous similar studies - as well as politics and organizational cultures that avoid change.

 

NICE-recommended clinical trial due to start on promising wound healing device

 

London (August 24, 2012) - The first clinical trial resulting from NICE medical technology guidance recommendations is due to start soon on a device to promote wound healing. NICE issued guidance in 2011 strongly encouraging further research on the use of the MIST Therapy system in chronic wounds, comparing it with standard care. The Medical Technologies Advisory Committee's view was that the device shows promise, but there was not yet enough evidence of sufficient quality to enable a recommendation for routine adoption of its use. The forthcoming clinical trial is the first significant output of the capacity that NICE has put in place for facilitating the development of further evidence, stemming from recommendations by NICE medical devices and diagnostics advisory bodies. The trial on the MIST Therapy system will recruit 40 patients with chronic venous leg ulcers, and will be undertaken independently by Cardiff University and Cardiff and Vale University Health Board.

 

The bottom photo shows a tattoo infected with a nontuberculous Mycobacteria (NTM) bacteria. It is provided courtesy of Matthew J. Mahlberg, M.D., Dermatology Associates of Colorado, Englewood, Colo., and was obtained by Sarah Jackson, MPH, Colorado Department of Public Health and Environment.Tattoo Inks Pose Health Risks

 

Silver Spring, MD, USA (August 23, 2012) - Tempted to get a tattoo? Today, people from all walks of life have tattoos, which might lead you to believe that tattoos are completely safe.

But there are health risks that can result in the need for medical care. The Food and Drug Administration (FDA) is particularly concerned about a family of bacteria called nontuberculous Mycobacteria (NTM) that has been found in a recent outbreak of illnesses linked to contaminated tattoo inks.

 

Study underscores need to improve communication with moms of critically ill infants

 

Baltimore, MD, USA (August 16, 2012) - Irish playwright George Bernard Shaw once described England and America as two countries separated by a common language. Now research from the Johns Hopkins Children's Center suggests that common language may also be the divide standing between mothers of critically ill newborns and the clinicians who care for them.

The study, published August 16 in the Journal of Perinatology, found that miscommunication was common, and that the most serious breakdown in communication occurred when mothers and clinicians discussed the severity of the baby's condition. Misunderstanding was common even when both the doctor and the mother agreed their conversations went well, suggesting a startling lack of awareness of the problem, the researchers say.

 

FDA warns of risk of death from codeine use in some children following surgeries

 

Silver Spring, MD, USA (August 15, 2012) - The U.S. Food and Drug Administration today issued a Drug Safety Communication concerning three children who died and one child who experienced a non-fatal but life-threatening case of respiratory depression after taking the pain reliever codeine following surgery to remove tonsils (tonsillectomy) and/or adenoids (adenoidectomy).

 

Egg yolk consumption almost as bad as smoking when it comes to atherosclerosis

 

London, Ontario, Canada (August 13, 2012) - Newly published research led by Dr. David Spence of Western University, Canada, shows that eating egg yolks accelerates atherosclerosis in a manner similar to smoking cigarettes. Surveying more than 1200 patients, Dr. Spence found regular consumption of egg yolks is about two-thirds as bad as smoking when it comes to increased build-up of carotid plaque, a risk factor for stroke and heart attack. The research is published online in the journal Atherosclerosis.

 

Diabetes drugs taken by over 15 million Americans raises risk of bladder cancer

 

PHILADELPHIA, PA, USA (August 13, 2012) - A popular class of diabetes drugs increases patients' risk of bladder cancer, according to a new study published online this month in the Journal of the National Cancer Institute. Researchers from the Perelman School of Medicine at the University of Pennsylvania found that patients taking thiazolidinedione (TZDs) drugs – which account for up to 20 percent of the drugs prescribed to diabetics in the United States -- are two to three times more likely to develop bladder cancer than those who took a sulfonylurea drug, another common class of medications for diabetes.